Castleark Management LLC Invests $2.31 Million in Repligen Co. (NASDAQ:RGEN)

Castleark Management LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 15,500 shares of the biotechnology company's stock, valued at approximately $2,307,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Andra AP fonden bought a new stake in Repligen during the second quarter worth about $25,000. International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter worth approximately $33,000. UMB Bank n.a. boosted its holdings in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after buying an additional 130 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares in the last quarter. Finally, Quarry LP increased its holdings in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after buying an additional 239 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

NASDAQ:RGEN traded up $6.94 during mid-day trading on Friday, hitting $149.20. 590,853 shares of the stock were exchanged, compared to its average volume of 693,035. The firm's 50-day simple moving average is $141.45 and its 200 day simple moving average is $141.82. The stock has a market capitalization of $8.36 billion, a price-to-earnings ratio of -403.24, a price-to-earnings-growth ratio of 4.48 and a beta of 0.96. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the firm earned $0.23 earnings per share. The company's revenue was up 9.7% on a year-over-year basis. As a group, equities analysts anticipate that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on RGEN shares. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target on the stock. Finally, StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.